Esperion Therapeutics (ESPR) Current Leases (2019 - 2026)

Esperion Therapeutics has reported Current Leases for 8 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 39.79% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (down 39.79% YoY), and the FY2025 full-year result was $2.1 million, down 23.31% from the prior year.
• Current Leases for Q1 2026 stood at $1.7 million, down from $2.1 million in the prior quarter.
• The five-year high for Current Leases was $2.8 million in Q1 2025, with the low at $305000.0 in Q1 2023.
• Historically, Current Leases has averaged $1.7 million across 5 years, with a median of $1.7 million in 2026.
• Annual changes were most pronounced in 2023 — Current Leases plunged 74.94% — and 2024, when it soared 732.46%.
• Esperion Therapeutics' Current Leases stood at $384000.0 in 2022, then jumped by 304.43% to $1.6 million in 2023, then surged by 76.5% to $2.7 million in 2024, then dropped by 23.31% to $2.1 million in 2025, then slipped by 19.17% to $1.7 million in 2026.
• The last three Current Leases figures came in at $1.7 million (Q1 2026), $2.1 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.